按品牌選擇
 |
|
|||||||||||||||||||||||||||||||||
| [發(fā)表評(píng)論] [本類(lèi)其他產(chǎn)品] [本類(lèi)其他供應(yīng)商] [收藏] | ||||||||||||||||||||||||||||||||||
| 銷(xiāo)售商： TargetMol中國(guó) | 查看該公司所有產(chǎn)品 >> |
Product Introduction
Bioactivity
英文名: Mavorixafor
描述: Mavorixafor (AMD-070) 是一種有效的特異性 CXCR4 拮抗劑，對(duì) CXCR4 125I-SDF 結(jié)合的 IC50 值為 13 nM。 Mavorixafor 在 MT-4 細(xì)胞 (IC50 = 1 nM) 和 PBMC (IC50 = 9 nM) 中抑制 T-tropic HIV-1 (NL4.3 株) 的復(fù)制。
細(xì)胞實(shí)驗(yàn): Cells are seeded on a 96-well plate at 5 × 10^3 cells/well in DMEM containing 10% FCS. Twenty-four hours later, the cells are treated with or without 2 ?M AMD3100 or 6.6 ?M AMD-070. After 24 or 48 h, the number of cells is quantified by an assay using MTT [2].
動(dòng)物實(shí)驗(yàn): BALB/c nude mice are maintained under pathogen-free conditions. The experiments are initiated when the mice are 8 weeks of age. Briefly, the cells are inoculated into the blood vessels of nude mice (1× 10^6). These mice are sacrificed at day 49. The presence or absence of distant metastases is confirmed by hematoxylin and eosin (H&E) staining. For experimental chemotherapy, the mice are treated by the daily oral administration of 0.2 mL of saline for a vehicle or the same volume of AMD-070 (2 mg/kg) [2].
體外活性: Mavorixafor (6.6 ?M) 顯著降低了B88-SDF-1細(xì)胞的錨定依賴(lài)性生長(zhǎng)、遷移和Matrigel侵襲[1]。Mavorixafor 對(duì)其他趨化因子受體（CCR1、CCR2b、CCR4、CCR5、CXCR1和CXCR2）無(wú)影響[2]。
體內(nèi)活性: AMD-070 (2 mg/kg，p.o.) 在小鼠中顯著減少了肺轉(zhuǎn)移結(jié)節(jié)的數(shù)量，并降低了小鼠體內(nèi)人源Alu DNA的表達(dá)，而不引起體重減輕[1]。
存儲(chǔ)條件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
溶解度: Ethanol : 44 mg/mL (125.9 mM)
H2O : 7 mg/mL (20.03 mM)
DMSO : 17 mg/mL (48.64 mM)
關(guān)鍵字: CXCR | Mavorixafor | Human immunodeficiency virus | AMD070 | HIV | inhibit | CXC chemokine receptors | AMD 070 | Inhibitor
相關(guān)產(chǎn)品: Reparixin | ATI-2341 acetate(1337878-62-2 free base) | ITIC | AMD 3465 hexahydrobromide | CXCR4-IN-2 | ITIC-4F | Baohuoside I | Motixafortide | CXCR4-IN-1 | AZD8797
相關(guān)庫(kù): Drug Repurposing Compound Library | ReFRAME Related Library | Anti-Cancer Drug Library | Membrane Protein-targeted Compound Library | Bioactive Compounds Library Max | Inhibitor Library | GPCR Compound Library | Anti-Cancer Clinical Compound Library | Pediatric Drug Library | Anti-Viral Compound Library
Bioactivity
英文名: Mavorixafor
描述: Mavorixafor (AMD-070) 是一種有效的特異性 CXCR4 拮抗劑，對(duì) CXCR4 125I-SDF 結(jié)合的 IC50 值為 13 nM。 Mavorixafor 在 MT-4 細(xì)胞 (IC50 = 1 nM) 和 PBMC (IC50 = 9 nM) 中抑制 T-tropic HIV-1 (NL4.3 株) 的復(fù)制。
細(xì)胞實(shí)驗(yàn): Cells are seeded on a 96-well plate at 5 × 10^3 cells/well in DMEM containing 10% FCS. Twenty-four hours later, the cells are treated with or without 2 ?M AMD3100 or 6.6 ?M AMD-070. After 24 or 48 h, the number of cells is quantified by an assay using MTT [2].
動(dòng)物實(shí)驗(yàn): BALB/c nude mice are maintained under pathogen-free conditions. The experiments are initiated when the mice are 8 weeks of age. Briefly, the cells are inoculated into the blood vessels of nude mice (1× 10^6). These mice are sacrificed at day 49. The presence or absence of distant metastases is confirmed by hematoxylin and eosin (H&E) staining. For experimental chemotherapy, the mice are treated by the daily oral administration of 0.2 mL of saline for a vehicle or the same volume of AMD-070 (2 mg/kg) [2].
體外活性: Mavorixafor (6.6 ?M) 顯著降低了B88-SDF-1細(xì)胞的錨定依賴(lài)性生長(zhǎng)、遷移和Matrigel侵襲[1]。Mavorixafor 對(duì)其他趨化因子受體（CCR1、CCR2b、CCR4、CCR5、CXCR1和CXCR2）無(wú)影響[2]。
體內(nèi)活性: AMD-070 (2 mg/kg，p.o.) 在小鼠中顯著減少了肺轉(zhuǎn)移結(jié)節(jié)的數(shù)量，并降低了小鼠體內(nèi)人源Alu DNA的表達(dá)，而不引起體重減輕[1]。
存儲(chǔ)條件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
溶解度: Ethanol : 44 mg/mL (125.9 mM)
H2O : 7 mg/mL (20.03 mM)
DMSO : 17 mg/mL (48.64 mM)
關(guān)鍵字: CXCR | Mavorixafor | Human immunodeficiency virus | AMD070 | HIV | inhibit | CXC chemokine receptors | AMD 070 | Inhibitor
相關(guān)產(chǎn)品: Reparixin | ATI-2341 acetate(1337878-62-2 free base) | ITIC | AMD 3465 hexahydrobromide | CXCR4-IN-2 | ITIC-4F | Baohuoside I | Motixafortide | CXCR4-IN-1 | AZD8797
相關(guān)庫(kù): Drug Repurposing Compound Library | ReFRAME Related Library | Anti-Cancer Drug Library | Membrane Protein-targeted Compound Library | Bioactive Compounds Library Max | Inhibitor Library | GPCR Compound Library | Anti-Cancer Clinical Compound Library | Pediatric Drug Library | Anti-Viral Compound Library
手機(jī)版：Mavorixafor
- 中國(guó)生物化學(xué)與分子生物學(xué)會(huì)2025全國(guó)學(xué)術(shù)大會(huì)招商函
- MCE推出生命科學(xué)文獻(xiàn)有投必獎(jiǎng)活動(dòng)(腫瘤與癌癥)
- 睿通生物推出新品ML19熔融石英折射率匹配液
- MCE直播：同位素標(biāo)記物示蹤劑與定量?jī)?nèi)標(biāo)品的探索
- MCE邀您參加2024年滿(mǎn)意度有獎(jiǎng)?wù){(diào)查&感恩節(jié)回饋活動(dòng)
- MCE暖冬鉅惠：染料、siRNA65折，享1.5倍牌價(jià)積分
- MCE中國(guó)11月展會(huì)預(yù)告: 蘇州生物藥創(chuàng)新開(kāi)發(fā)峰會(huì)等
- MCE直播：癌癥中的炎癥反應(yīng)&細(xì)胞焦亡的思路與方法
- 放射性核素RDC在腫瘤診斷與治療中應(yīng)用和發(fā)展前景
- FITC-xtra 異硫氰酸熒光素的優(yōu)勢(shì)及實(shí)驗(yàn)方案步驟
- α-淀粉酶測(cè)定試劑盒 (Ceralpha Method)原理與使用
- 納米管介導(dǎo)的線(xiàn)粒體轉(zhuǎn)移在腫瘤免疫治療研究中的應(yīng)用
- 分子動(dòng)力學(xué)模擬技術(shù)在藥物研發(fā)領(lǐng)域的應(yīng)用前景及核心原理
- 紅霉素MTS藥敏紙條助力抗擊耐藥精準(zhǔn)檢測(cè)
- 大腸桿菌不耐熱腸毒素(LT)試劑盒使用說(shuō)明書(shū)
- 蛋白降解技術(shù)AUTOTAC、第一代和第二代AUTAC的作用機(jī)制
更多
瀏覽該公司同類(lèi)產(chǎn)品
瀏覽該公司同類(lèi)產(chǎn)品更多瀏覽其他公司同類(lèi)產(chǎn)品
瀏覽其他公司同類(lèi)產(chǎn)品
Copyright(C) 1998-2025 生物器材網(wǎng) 電話(huà)：021-64166852;13621656896 E-mail：info@bio-equip.com